[PREVIEW] Why European patients still can’t access 100 new drugs ?
![[PREVIEW] Why European patients still can’t access 100 new drugs ?](https://image.ausha.co/sRAfTuU8a3bruOfDqKWfx50dFinNWQD0FKbLVyPN_1400x1400.jpeg?t=1761295219 "[PREVIEW] Why European patients still can’t access 100 new drugs ?")
Hundreds of breakthrough treatments are transforming patients’ lives in the US — but still aren’t available in Europe.
In this short extract, Pierre-Henri Belin, the Co-Founder and CEO of Xcube.Bio, reveals the shocking scale of this innovation gap… and why it’s growing.
The full episode drops tomorrow on Pharma minds — don’t miss it!
What you will learn in the full episode of tomorrow :
◾️ The alarming gap between the United States and Europe — with more than 100 new drugs available in the US but still not accessible to European patients.
◾️ Why this gap exists, from fragmented regulatory systems to national-level decision-making and the lack of early collaboration between key actors.
◾️ The consequences for patients, innovation, and the competitiveness of Europe’s healthcare ecosystem.
◾️ Pierre-Henri’s proposed model, built on transparency, collaboration, and shared responsibility — connecting innovators, regulators, and patients earlier in the process.
◾️ A message of hope, showing that Europe can reinvent its system without sacrificing safety or trust, but only if we act collectively and decisively.
A clear, concrete, and inspiring episode that sheds light on how Europe can regain its leadership in healthcare innovation.
See you tomorrow!
---
🎧 New here? To get a quick overview of the episodes, download “25 Tips for Purposeful Leadership”, a guide inspired by the best advice shared by my guests.
🤝 Want to connect or talk about your current challenges? Let’s connect on LinkedIn.
📩 Curious to dive deeper into the major shifts in the pharma and healthcare ecosystem? Subscribe to the Pharma Minds newsletter.
Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.
1
00:00:01.129 --> 00:00:03.491
Hello everyone and welcome to PharmaMinds,
2
00:00:03.612 --> 00:00:08.157
the podcast that takes you behind the scenes with the leading figures in the pharma world.
3
00:00:08.278 --> 00:00:08.653
New week,
4
00:00:08.793 --> 00:00:09.473
new episode,
5
00:00:09.614 --> 00:00:14.184
and here's a sneak peek of the conversation you can catch online starting tomorrow.
6
00:00:15.161 --> 00:00:19.942
There are hundreds and if not thousands of new molecular entities,
7
00:00:19.943 --> 00:00:24.535
so new drugs that are phase 2 plus and are not partners.
8
00:00:25.940 --> 00:00:28.100
And we see this big wave of innovation,
9
00:00:28.141 --> 00:00:30.223
which is absolutely great news for patients.
10
00:00:32.063 --> 00:00:36.199
It's getting through a lot of disease with no treatment at the moment,
11
00:00:36.200 --> 00:00:38.426
a lot of often a lot of neglected diseases.
12
00:00:40.762 --> 00:00:42.231
And when you look at the statistics,
13
00:00:42.246 --> 00:00:43.137
and it's not my statistics,
14
00:00:43.168 --> 00:00:44.324
it's QVR statistics,
15
00:00:44.340 --> 00:00:50.621
there are more than 100 drugs that have been launched in the US in the last five years that are not in Europe,
16
00:00:50.731 --> 00:00:50.965
right?
17
00:00:51.106 --> 00:00:54.403
And we see this number is very constantly growing.
18
00:00:55.380 --> 00:00:55.941
Unfortunately,
19
00:00:56.881 --> 00:00:59.004
and it means just it's as simple as that,
20
00:00:59.005 --> 00:01:05.268
is that patients in Europe are not treated the same way as in the US and have not access to the same type of drug rights.
21
00:01:05.549 --> 00:01:08.533
And here we're really talking about new molecular entities.
22
00:01:08.534 --> 00:01:09.112
So not even,
23
00:01:10.455 --> 00:01:10.697
you know,
24
00:01:11.057 --> 00:01:13.994
similar or generics or things like that.
25
00:01:14.322 --> 00:01:15.494
If you enjoyed this snippet,
26
00:01:15.619 --> 00:01:21.713
remember to subscribe on this app and turn on the notifications to be the first to know when the full episode is out.
27
00:01:22.100 --> 00:01:26.367
Wishing you a fantastic listening experience and I'll see you soon on PharmaMinds.
